» Articles » PMID: 28411178

MicroRNA Expression Profiling of Xp11 Renal Cell Carcinoma

Overview
Journal Hum Pathol
Specialty Pathology
Date 2017 Apr 16
PMID 28411178
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Renal cell carcinomas (RCCs) with Xp11 translocation (Xp11 RCC) constitute a distinctive molecular subtype characterized by chromosomal translocations involving the Xp11.2 locus, resulting in gene fusions between the TFE3 transcription factor with a second gene (usually ASPSCR1, PRCC, NONO, or SFPQ). RCCs with Xp11 translocations comprise up to 1% to 4% of adult cases, frequently displaying papillary architecture with epithelioid clear cells. To better understand the biology of this molecularly distinct tumor subtype, we analyze the microRNA (miRNA) expression profiles of Xp11 RCC compared with normal renal parenchyma using microarray and quantitative reverse-transcription polymerase chain reaction. We further compare Xp11 RCC with other RCC histologic subtypes using publically available data sets, identifying common and distinctive miRNA signatures along with the associated signaling pathways and biological processes. Overall, Xp11 RCC more closely resembles clear cell rather than papillary RCC. Furthermore, among the most differentially expressed miRNAs specific for Xp11 RCC, we identify miR-148a-3p, miR-221-3p, miR-185-5p, miR-196b-5p, and miR-642a-5p to be up-regulated, whereas miR-133b and miR-658 were down-regulated. Finally, Xp11 RCC is most strongly associated with miRNA expression profiles modulating DNA damage responses, cell cycle progression and apoptosis, and the Hedgehog signaling pathway. In summary, we describe here for the first time the miRNA expression profiles of a molecularly distinct type of renal cancer associated with Xp11.2 translocations involving the TFE3 gene. Our results might help understanding the molecular underpinning of Xp11 RCC, assisting in developing targeted treatments for this disease.

Citing Articles

Nonsense-Mediated Decay Targeted RNA (ntRNA): Proposal of a ntRNA-miRNA-lncRNA Triple Regulatory Network Usable as Biomarker of Prognostic Risk in Patients with Kidney Cancer.

Zhou Z, Hu F, Huang D, Chi Q, Tang N Genes (Basel). 2022; 13(9).

PMID: 36140823 PMC: 9498815. DOI: 10.3390/genes13091656.


MicroRNA‑642a‑5p inhibits colon cancer cell migration and invasion by targeting collagen type I α1.

Wang X, Song Z, Hu B, Chen Z, Chen F, Cao C Oncol Rep. 2021; 45(3):933-944.

PMID: 33650641 PMC: 7859924. DOI: 10.3892/or.2020.7905.


The suitability of NONO-TFE3 dual-fusion FISH assay as a diagnostic tool for NONO-TFE3 renal cell carcinoma.

Liu N, Guo W, Shi Q, Zhuang W, Pu X, Chen S Sci Rep. 2020; 10(1):16361.

PMID: 33004995 PMC: 7530984. DOI: 10.1038/s41598-020-73309-4.


Comparative transcriptomics of primary cells in vertebrates.

Alam T, Agrawal S, Severin J, Young R, Andersson R, Arner E Genome Res. 2020; 30(7):951-961.

PMID: 32718981 PMC: 7397866. DOI: 10.1101/gr.255679.119.


CircUBAP2 Inhibits Proliferation and Metastasis of Clear Cell Renal Cell Carcinoma via Targeting miR-148a-3p/FOXK2 Pathway.

Sun J, Yin A, Zhang W, Lv J, Liang Y, Li H Cell Transplant. 2020; 29:963689720925751.

PMID: 32425115 PMC: 7563813. DOI: 10.1177/0963689720925751.


References
1.
Argani P, Hicks J, De Marzo A, Albadine R, Illei P, Ladanyi M . Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol. 2010; 34(9):1295-303. PMC: 3449149. DOI: 10.1097/PAS.0b013e3181e8ce5b. View

2.
Sukov W, Hodge J, Lohse C, Leibovich B, Thompson R, Pearce K . TFE3 rearrangements in adult renal cell carcinoma: clinical and pathologic features with outcome in a large series of consecutively treated patients. Am J Surg Pathol. 2012; 36(5):663-70. DOI: 10.1097/PAS.0b013e31824dd972. View

3.
Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

4.
Green W, Yonescu R, Morsberger L, Morris K, Netto G, Epstein J . Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service. Am J Surg Pathol. 2013; 37(8):1150-63. DOI: 10.1097/PAS.0b013e31828a69ae. View

5.
Munari E, Marchionni L, Chitre A, Hayashi M, Martignoni G, Brunelli M . Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. Hum Pathol. 2014; 45(6):1130-8. PMC: 4332813. DOI: 10.1016/j.humpath.2014.01.013. View